This approach, alongside to permit the evaluation of the effective pharmacological action of the drug in tumor cells, could allow also to monitor at individual level the inhibition of a downstream signaling pathway associated with cancer progression, stating its effective dependence on Src activity. Here, SRC is linked to neoplasm.